Bad medicine
- Share via
Re “Generic solution,” editorial, Feb. 24
The problem facing seniors in the availability of low-cost generics is further illustrated by the formulary of one of the state’s largest Medicare Part D providers. Although the brand-name drug is available under the formulary, the generic is not, thus increasing the cost of the prescription drug to the senior consumer.
By including only the brand-name product, the cost to the Medicare recipient is increased, which may provide a greater profit to the Part D provider.
How many other low-cost generics are denied to Medicare Part D subscribers?
SELWYN BRENT
Huntington Beach
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
